Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine
In 2020, SARS-COV-2 put health systems under unprecedented resource and manpower pressure leading to significant number of deaths. Expectedly, researchers sought to shed light on the pathophysiologic background of this novel disease (COVID-19) as well as to facilitate the design of effective therape...
Guardado en:
Autores principales: | Dimitrios A. Vrachatis, Konstantinos A. Papathanasiou, Sotiria G. Giotaki, Konstantinos Raisakis, Charalampos Kossyvakis, Andreas Kaoukis, Fotis Kolokathis, Gerasimos Deftereos, Konstantinos E. Iliodromitis, Dimitrios Avramides, Harilaos Bogossian, Gerasimos Siasos, George Giannopoulos, Bernhard Reimers, Alexandra Lansky, Jean-Claude Tardif, Spyridon Deftereos |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7f199d476d6340c69eb0fd2256992511 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Impact of colchicine on mortality in patients with COVID-19: A meta-analysis
por: Dimitrios A. Vrachatis, et al.
Publicado: (2021) -
Endocan: A Novel Marker for Colchicine Resistance in Familial Mediterranean Fever Patients?
por: Ahmet Omma, et al.
Publicado: (2021) -
Neutrophil Extracellular Traps (NETs) and Hypercoagulability in Plasma Cell Dyscrasias—Is This Phenomenon Worthy of Exploration?
por: Olga Ciepiela, et al.
Publicado: (2021) -
Serum hypercoagulability states in Coats’ disease
por: Ghassemi F, et al.
Publicado: (2017) -
Recurrence of the oxazole motif in tubulin colchicine site inhibitors with anti-tumor activity
por: Marilia Barreca, et al.
Publicado: (2021)